Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

This trial is testing a new type of immune cell therapy — engineered NK (natural killer) cells that target a protein called TROP2 — combined with the drug cetuximab, in colorectal cancer patients who have had successful surgery and standard follow-up treatment but still have very small, undetectable traces of cancer (called minimal residual disease or MRD) detected through a blood test. **You may be eligible if...** - You are 18 or older - You have been diagnosed with colorectal cancer, had complete surgical removal of your tumor, and completed standard follow-up chemotherapy - Blood tests show signs of minimal residual disease (cancer DNA in the blood) even though imaging shows no visible cancer - You are in good overall health and able to follow study requirements **You may NOT be eligible if...** - You have visible cancer remaining or that has returned on scans - You have serious immune system problems or active autoimmune disease - You have significant heart, liver, or kidney dysfunction - You are pregnant or breastfeeding - You have had prior CAR-T or NK cell therapies Talk to your doctor to see if this trial is right for you.